Calamos Advisors

Calamos Advisors’s Envoy Medical COCH Stock Holding History

Calamos Advisors’s Portfolio COCH Stock Details COCH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-300,000	Closed	-$3.03M	–	1149
2022 Q4	$3.03M	Buy	+300,000	New	+$2.98M	0.01%	746

Other funds holding COCH

Atlas Merchant Capital New York $789K AUM 60.67% 1-Year Est. Return

Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return

Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return

Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Citadel Advisors

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Calamos Advisors's COCH Position: Q1 2023 in Review

Calamos Advisors sold out of Envoy Medical (COCH) in Q1 2023, closing a stake of 300,000 shares — an estimated $3.03M sold.

Calamos Advisors first reported a position in COCH in Q4 2022 and held it in 1 quarter. The position peaked at $3.03M in Q4 2022. 24 funds tracked by Wall St. Rank hold COCH as of Q1 2023.

Calamos Advisors reported no remaining Envoy Medical position as of Q1 2023 after selling out during the quarter.
Calamos Advisors sold 300,000 Envoy Medical shares in Q1 2023, an estimated $3.03M.
Calamos Advisors first reported a position in Envoy Medical in Q4 2022 and held it in 1 quarter.
Calamos Advisors's Envoy Medical position peaked at $3.03M in Q4 2022.
24 funds tracked by Wall St. Rank held Envoy Medical as of Q1 2023.

Based on Calamos Advisors's 13F filing for Q1 2023, filed 4 May 2023.